Návratnost kapitálu společnosti ProMIS Neurosciences
Jaká je hodnota metriky Návratnost kapitálu společnosti ProMIS Neurosciences?
Hodnota metriky Návratnost kapitálu společnosti ProMIS Neurosciences, Inc. je 0.00%
Jaká je definice metriky Návratnost kapitálu?
Return on capital employed (ROCE) je finanční ukazatel, který měří rentabilitu společnosti a efektivitu společnosti ve využívání vlastního kapitálu.
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
Návratnost kapitálu společností v sektoru Health Care sektor na TSX ve srovnání se společností ProMIS Neurosciences
Čemu se věnuje společnost ProMIS Neurosciences?
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Firmy s metrikou návratnost kapitálu podobnou společnosti ProMIS Neurosciences
- Hodnota metriky Návratnost kapitálu společnosti Omega Alpha Spac je -0.01%
- Hodnota metriky Návratnost kapitálu společnosti The Gap je -0.01%
- Hodnota metriky Návratnost kapitálu společnosti Elemental Royalties Ltd je -0.01%
- Hodnota metriky Návratnost kapitálu společnosti Auburn National Bancorp je -0.01%
- Hodnota metriky Návratnost kapitálu společnosti Galaxy Digital je -0.01%
- Hodnota metriky Návratnost kapitálu společnosti The Gap je -0.01%
- Hodnota metriky Návratnost kapitálu společnosti ProMIS Neurosciences je 0.00%
- Hodnota metriky Návratnost kapitálu společnosti Tejon Ranch Co je 0.01%
- Hodnota metriky Návratnost kapitálu společnosti Glen Burnie Bancorp je 0.02%
- Hodnota metriky Návratnost kapitálu společnosti MSP Steel & Power je 0.02%
- Hodnota metriky Návratnost kapitálu společnosti TTL Beteiligungs- und Grundbesitz-AG je 0.03%
- Hodnota metriky Návratnost kapitálu společnosti First Foundation Inc je 0.03%
- Hodnota metriky Návratnost kapitálu společnosti FirstMark Horizon Acquisition je 0.03%